Phosphorothioate oligonucleotides reduce PrPSc levels and prion infectivity in cultured cells

Molecular Medicine

Volumn 13, Issue 3-4, 2007, Pages 190-198

  Karpuj, Marcela V ^a,c   Giles, Kurt ^a,b   Gelibter Niv, Sagit ^c   Scott, Michael R ^a,b,e   Lingappa, Vishwanath R ^a   Szoka, Francis C ^a   Peretz, David ^a,b,f   Denetclaw, Wilfred ^d   Prusiner, Stanley B ^a,b,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d SAN FRANCISCO STATE UNIVERSITY   (United States)

^e UNIVERSITY COLLEGE DUBLIN   (Ireland)

^f NOVARTIS   (United States)

^g Institute for Neurodegenerative Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PRION PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA TRANSFECTION; DRUG EFFICACY; GRANULE CELL; HIPPOCAMPUS; HUMAN; HUMAN CELL; MOUSE; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL;

ANIMALS; BINDING, COMPETITIVE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCEINS; FLUORESCENT DYES; MICE; MICE, TRANSGENIC; NEUROBLASTOMA; OLIGONUCLEOTIDES; PHOSPHATES; PRIONS; PRPC PROTEINS; PRPSC PROTEINS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 34250658005     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/2006-00073.Karpuj     Document Type: Article

References (54)

1. Cotzias GC, Van Woert MH, Schiffer LM. (1967) Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med. 276:374-9.
2. Prusiner SB. (2004) Prion Biology and Diseases. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, p. 1050.
3. Legname G, Baskakov IV, Nguyen H-OB, et al. (2004) Synthetic mammalian prions. Science. 305:673-6.
4. Tanaka M, Chien P, Naber N, Cooke R, Weissman JS. (2004) Conformational variations in an infectious protein determine prion strain differences. Nature. 428:323-8.
5. Korth C et al. (2003) Abbreviated incubation times for human prions in mice expressing a chimeric mouse - human prion protein transgene. Proc. Natl. Acad. Sci. U. S. A. 100:4784-9.
6. Prusiner SB et al. (1993) Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc. Natl. Acad. Sci. U.S.A. 90:10608-12.
7. Sc levels but delayed onset of disease in scrapie-inoculated mice heterozygous for a disrupted PrP gene. Mol. Med. 1:19-30.
8. Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, Collinge J. (2003) Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science. 302:871-4.
9. Safar JG et al. (2005) Prion clearance in bigenic mice. J. Gen. Virol. 86:2913-23.
10. Doh-ura K, Iwaki T, Caughey B. (2000) Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J. Virol. 74:4894-7.
11. Perrier V, Wallace AC, Kaneko K, Safar J, Prusiner SB, Cohen FE. (2000) Mimicking dominant negative inhibition of prion replication through structure-based drug design. Proc. Natl. Acad. Sci. U. S. A. 97:6073-8.
12. Korth C, May BCH, Cohen FE, Prusiner SB. (2001) Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Natl. Acad. Sci. U. S. A 98:9836-41.
13. Kocisko DA, Baron GS, Rubenstein R, Chen J, Kuizon S, Caughey B. (2003) New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J. Virol. 77:10288-94.
14. Supattapone S, Nguyen H-OB, Cohen FE, Prusiner SB, Scott MR. (1999) Elimination of prions by branched polyamines and implications for therapeutics. Proc. Natl. Acad. Sci. U. S. A. 96:14529-34.
15. Peretz D et al. (2001) Antibodies inhibit prion propagation and clear cell cultures of prion infectiviry. Nature. 412:739-43.
16. Enari M, Flechsig E, Weissmann C. (2001) Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc. Natl. Acad. Sci. U. S. A. 98:9295-9.
17. Heppner FL et al. (2001) Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science. 294: 178-182.
18. Sigurdsson EM et al. (2003) Anti-prion antibodies for prophylaxis following prion exposure in mice. Neurosci. Lett. 336:185-7.
19. White AR et al. (2003) Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature. 422:80-3.
20. May BCH et al. (2003) Potent inhibition of scrapie prion replication in cultured cells by bis-acridines. Proc. Natl. Acad. Sci. U. S. A. 100:3416-21.
21. Collins SJ, Lewis V, Brazier M, Hill AF, Fletcher A, Masters CL. (2002) Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann. Neurol. 52:503-6.
22. Barret A et al. (2003) Evaluation of quinacrine treatment for prion diseases. J. Virol. 77:8462-9.
23. Doh-ura K et al. (2004) Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J. Virol. 78:4999-5006.
24. Sethi S, Lipford G, Wagner H, Kretzschmar H. (2002) Postexposure prophylaxis against prion disease with a stimulator of innate immunity. Lancet. 360:229-30.
25. Stein CA, Cheng YC. (1993) Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science. 261:1004-12.
26. Prusiner SB, May BCH, Cohen FE. (2004) Therapeutic approaches to prion diseases. In: Prusiner SB (ed.) Prion Biology and Diseases. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp. 961-1014.
27. Kocisko DA et al. (2006) Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides. Antimicrob. Agents Chemother. 50:1034-44.
28. Butler DA et al. (1988) Scrapie-infected murine neuroblastoma cells produce protease-resistant prion proteins. J. Virol. 62:1558-64.
29. Bosque PJ, Prusiner SB. (2000) Cultured cell sublines highly susceptible to prion infection. J. Virol. 74:4377-86.
30. Kanaani J, Prusiner SB, Diacovo J, Baekkeskov S, Legname G. (2005) Recombinant prion protein induces rapid polarization and development of synapses in embryonic rat hippocampal neurons in vitro. J. Neurochem. 95:1373-86.
31. Williamson RA et al. (1998) Mapping the prion protein using recombinant antibodies. J. Virol. 72:9413-8.
32. Peretz D et al. (1997) A conformational transition at the N-terminus of the prion protein features in formation of the scrapie isoform. J. Mol. Biol. 273:614-22.
33. Moore RC et al. (1999) Ataxia in prion protein (PrP)-deficient mice is associated with upregulation of the novel PrP-like protein doppel. J. Mol. Biol. 292:797-817.
34. Muramoto T, DeArmond SJ, Scott M, Telling GC, Cohen FE, Prusiner SB. (1997) Heritable disorder resembling neuronal storage disease in mice expressing prion protein with deletion of an a-helix. Nat. Med. 3:750-5.
35. Krieg AM et al. (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:546-9.
36. Schätzl HM et al. (1997) A hypothalamic neuronal cell line persistently infected with scrapie prions exhibits apoptosis. J. Virol. 71:8821-31.
37. Stahl N, Borchelt DR, Hsiao K, Prusiner SB. (1987) Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell. 51:229-40.
38. He H-T, Finne J, Goridis C. (1987) Biosynthesis, membrane association, and release of N-CAM-120, a phosphatidylinositol-linked form of the neural cell adhesion molecule. J. Cell Biol. 105:2489-500.
39. Schmitt-Ulms G et al. (2001) Binding of neural cell adhesion molecules (N-CAMs) to the cellular prion protein. J. Mol. Biol. 314:1209-25.
40. fyn and to enhance neurite outgrowth. J. Cell Biol. 169: 41-54.
41. Matsunaga Y et al. (2001) Cryptic epitopes in N-terminally truncated prion protein are exposed in the full-length molecule: Dependence of conformation on pH. Proteins. 44:110-8.
42. C on the cell surface as probed by antibodies. J. Mol. Biol. 326:475-83.
43. Stenseth K, Thyberg J. (1989) Monensin and chloroquine inhibit transfer to lysosomes of endocytosed macromolecules in cultured mouse peritoneal macrophages. Eur. J. Cell Biol. 49:326-33.
44. Furuchi T, Aikawa K, Arai H, Inoue K. (1993) Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, blocks lysosomal cholesterol trafficking in macrophages. J. Biol. Chem. 268: 27345-8.
45. Yedidia Y, Horonchik L, Tzaban S, Yanai A, Taraboulos A. (2001) Proteasomes and ubiquitin are involved in the turnover of the wild-type prion protein. EMBO J. 20:5383-91.
46. C degradation. J. Neurochem. 89:454-63.
47. Williamson RA et al. (1996) Circumventing tolerance to generate autologous monoclonal antibodies to the prion protein. Proc. Natl. Acad. Sci. U. S. A 93:7279-82.
48. Leclerc E et al. (2001) Immobilized prion protein undergoes spontaneous rearrangement to a conformation having features in common with the infectious form. EMBO J. 20:1547-54.
49. Supattapone S et al. (2001) Branched polyamines cure prion-infected neuroblastoma cells. J. Virol. 75:3453-61.
50. Sc formation. Chembiochem. 3:717-25.
51. Res in vitro. J. Mol. Biol. 332:47-57.
52. Sayer NM, Cubin M, Rhie A, Bullock M, Tahiri-Alaoui A, James W. (2004) Structural determinants of conformational selective, prion-binding aptamers. J. Biol. Chem. 279:13102-9.
53. Takemura K et al. (2006) DNA aptamers that bind to PrP(C) and not PrP(Sc) show sequence and structure specificity. Exp. Biol. Med. 231:204-14.
54. King D, Safar JG, Legname G, Prusiner SB. (In press) Thioaptamer interactions with prion proteins: sequence-specific and non-specific binding sites. J. Mol. Biol.